The Indeterminate Answer
Clinical Vignette
A 31-year-old man presents to an HIV clinic after a new diagnosis of HIV-1 infection confirmed by fourth-generation antigen/antibody immunoassay and Western blot two weeks prior. He was referred from a community health center following a routine sexual health screening. He reports no prior HIV testing and denies any current symptoms. He has no significant past medical history and takes no medications. CD4 count is 118 cells/mcL and HIV-1 RNA is 48,500 copies/mL. He is a nonsmoker and reports no respiratory symptoms.
During the social history, he discloses that his male domestic partner of three years was diagnosed with pulmonary tuberculosis four weeks ago, confirmed by positive sputum AFB smear and culture growing pan-susceptible Mycobacterium tuberculosis. His partner has been on standard four-drug therapy for three weeks. The patient shares a one-bedroom apartment with his partner and reports no history of prior TB testing or treatment. He has never lived outside the United States and reports no international travel to TB-endemic regions.
On examination, temperature is 36.9°C, heart rate 84, blood pressure 118/74 mmHg, oxygen saturation 98% on room air. The physical examination is unremarkable. He specifically denies cough, hemoptysis, night sweats, and unintentional weight loss. A QuantiFERON-TB Gold Plus (QFT-Plus) is sent and the result returns indeterminate: the IFN-gamma response in the mitogen control tube falls below the minimum threshold required for valid interpretation, precluding a positive or negative classification. A posterior-anterior chest radiograph is obtained and is shown below.

Posterior-anterior chest radiograph obtained at initial evaluation.
Question 1
How should the indeterminate QuantiFERON result be interpreted, and what is the most appropriate next step?
Select one option to submit your answer and view live poll results.
Question 2
You plan rifamycin-based treatment. Which ART regimen is most appropriate?
Select one option to submit your answer and view live poll results.
Question 3
The patient asks about completing LTBI treatment as quickly as possible. Which statement about 1HP is most accurate?
Select one option to submit your answer and view live poll results.
References
Swindells S, Ramchandani R, Gupta A, et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis (BRIEF-TB/A5279). New England Journal of Medicine. 2019;380(11):1001-1011.
Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Department of Health and Human Services. 2024.
Dooley KE, Savic R, Gupte A, et al. Once-Daily Dolutegravir-Based Antiretroviral Therapy for HIV in Rifampicin-Based Treatment for TB in Adults (DOLPHIN-2): an open-label, randomised, non-inferiority trial. The Lancet HIV. 2020;7(6):e381-e387.
Sterling TR, Njie G, Zenner D, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recommendations and Reports. 2020;69(1):1-11.